InMed Pharmaceuticals Inc. (INM): R&D Expense
$3.03M
Year ended 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $3.03M | +7.3% | 2026-09-09, From 2025-07-01 |
| 2025-06-30 | $2.82M | n/c | 2026-09-09, From 2024-07-01 |
| 2024-06-30 | $3.22M | n/c | 2025-09-23, From 2023-07-01 |
| 2023-06-30 | $3.73M | -48.8% | 2024-09-30, From 2022-07-01 |
| 2022-06-30 | $7.28M | +36.4% | 2023-09-29, From 2021-07-01 |
| 2021-06-30 | $5.34M | -8.1% | 2022-09-23, From 2020-07-01 |
| 2020-06-30 | $5.81M | n/a | 2021-09-24, From 2019-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | 2026-06-30 | $3.03M | +7.3% |
| Hepion Pharmaceuticals, Inc. (HEPA) | 2025-12-31 | $445.5K | -96.2% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $1.36M | +276.5% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $3.64M | +19.5% |
| Palatin Technologies Inc (PTN) | 2025-06-30 | $14.90M | -33.5% |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $1.80M | -19.0% |
| Artelo Biosciences, Inc. (ARTL) | 2025-12-31 | $5.42M | -9.5% |
| Protagenic Therapeutics, Inc.\new (PTIX) | 2026-03-31 | $901.9K | +139.4% |
Compare INM, HEPA, TCRT, ATXI side by side · Screen every company in Pharmaceutical Preparations ↗